Followers | 25 |
Posts | 1513 |
Boards Moderated | 0 |
Alias Born | 12/14/2006 |
Thursday, February 13, 2014 6:39:58 PM
Perception is everything in the stock market (especially when you do not have actual earnings)
The NNVC hit piece was only effective because of the company's license/patents structure and the three layers of protection (protection for insiders). There are other ways to restructure the patents that are friendlier to the common shareholders and still offer poison pill takeover protection for insiders.
NNVC has not responded effectively to the hit piece. The damage has been done and suing the author will not bring back the stock price and will continue to drag out with (bad) press reminders, even if NNVC wins. The last four "news" releases are all lawsuits and this also plays into the shorts hand as it is a detriment to new potential investors, so the sooner we can put those behind us the better.
The stock can still recover quickly IF management acts to plug up this "perceived hole" that will come back and bite us on a seasonal basis until it is fixed. Insiders buying stock will not work this time because insiders already control too much for wallstreets liking (this is the perceived problem that insiders control NNVC stock and also have controlling interests in their other companies license/patents).
This is why they need to combine all the companies and restructure the poison pill to benefit all shareholders ASAP to make it crystal clear that ALL investors will benefit if the technology gets approval.
You can argue the details but you cannot argue with the stock price - that is 100% perception. IMHO
Disclaimer: Information is offered for discussion purposes only and is not guaranteed to be complete, unbiased, current or accurate and is subject to change without notice and is not be relied upon to make any investment decisions.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM